Daniele Robesti

Vita-Salute San Raffaele University

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Pavlos Msaouel

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Eva Corey

Professor

University of Washington

UNITED STATES

View details

Alberto Martini

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniele Robesti

Research Interests

Explore related searches

Contact this professor

Articles (10)

Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The neglected impact of informative censoring. A systematic review and meta-analysis

Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation

The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder

Endourological society fellowship program: a real contribution to improve surgical outcomes of stone patients treated with ureteroscopy

The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials.

Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer

Subtype and Site Specific-Induced Metabolic Vulnerabilities in Prostate Cancer.

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.

Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation.

Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.

Collaborators (3)

Pavlos Msaouel

Eva Corey

Alberto Martini

Make your next move.